← Product Code [ORG](/productcode/ORG) · BK230807 # Adaptive Autologous Processing System (BK230807) _Genesis Biologics, Inc. · ORG · May 10, 2023 · Hematology · SESE_ **Canonical URL:** https://fda.innolitics.com/device/BK230807 ## Device Facts - **Applicant:** Genesis Biologics, Inc. - **Product Code:** [ORG](/productcode/ORG.md) - **Decision Date:** May 10, 2023 - **Decision:** SESE - **Regulation:** 21 CFR 864.9245 - **Device Class:** Class 2 - **Review Panel:** Hematology ## Indications for Use The Adaptive Autologous Processing System™ (AAPS) is indicated to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of peripheral blood at the patient point-of-care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics. ## Device Story Single-use, sterile syringe assembly for autologous blood component separation; utilizes desktop centrifuge for density-based separation. Input: whole blood sample. Operation: blood drawn into main chamber; centrifugation separates plasma, buffy coat, and red blood cells; hollow threaded plunger with control valve allows aspiration of plasma/buffy coat into secondary chamber; red blood cells dispelled. Output: concentrated PRP for mixing with bone graft. Used at point-of-care by clinicians. Benefits: improved handling characteristics of bone graft materials for surgical applications. ## Clinical Evidence Bench testing only. Comparative study evaluated platelet concentrates from subject vs. predicate device. Metrics included platelet yields, recoveries, average concentration, pH, p-selectin expression, ADP-stimulation response, platelet function, aggregation, hypotonic stress response, and bone graft retention. All validations and qualifications met predetermined acceptance criteria. ## Technological Characteristics Syringe assembly with hollow threaded plunger and locking collar. Materials: Polycarbonate, Thermoplastic elastomer, silicone, Polyoxymethylene Copolymer. Principle: Density-based centrifugal separation. Energy: Manual. Connectivity: None. Sterilization: Ethylene oxide (ISO 11135, SAL 10⁻⁶). Form factor: 25mL syringe. ## Regulatory Identification An automated blood cell separator is a device that uses a centrifugal or filtration separation principle to automatically withdraw whole blood from a donor, separate the whole blood into blood components, collect one or more of the blood components, and return to the donor the remainder of the whole blood and blood components. The automated blood cell separator device is intended for routine collection of blood and blood components for transfusion or further manufacturing use. ## Special Controls *Classification.* Class II (special controls). The special control for this device is a guidance for industry and FDA staff entitled “Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Separation Principle.” ## Predicate Devices - Arthrex Double Syringe (ACP)® System ([BK190406](/device/BK190406.md)) ## Reference Devices - Healeon Duet ([BK200449](/device/BK200449.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} # 510(k) Summary Prepared: May 9, 2023 | I. | **Company** | Genesis Biologics, Inc. 16782 Von Karman Ave., Suite 17 Irvine, CA 92606 United States | | --- | --- | --- | | II. | **Contact** | Trevor J. Denbo Submissions Consultant +1.949.424.7607 | | III. | **Product Trade Name** | Adaptive Autologous Processing System | | IV. | **Common Name** | Platelet and Plasma Separator for Bone Graft Handling | | V. | **Classification Name** | Automated blood cell separator | | VI. | **Regulation Number** | 21 CFR 864.9245 | | VII. | **Device Class** | Class II | | VIII. | **Classification Product Code** | ORG | | IX. | **Predicate Device** | BK190406 Arthrex Double Syringe (ACP)® System | # X. **Description** The *Adaptive Autologous Processing System* is a sterile, single use, syringe assembly that is intended for separating and concentrating blood components along with the use of a desktop centrifuge. It enables blood to be separated and aspirated in a single device after centrifugation. The *Adaptive Autologous Processing System* consists of a syringe with a hollow threaded plunger that provides a secondary chamber and locking collar that engages the thread plunger for the controlled collection of whole blood and the separation of platelet rich plasma. A sample is introduced to the main chamber of the syringe, the locking collar is engaged, and centrifugation is performed. The whole blood is separated into discrete gradient layers based upon density with the plasma located on top and the buffy coat suspended directly below followed by the red blood cells at the distal end of the syringe. The secondary chamber located inside the plunger is opened through a control valve and with a twisting motion downward the upper plasma layer securely enters the secondary chamber until the buffy coat is captured. Once the plasma and buffy coat are secured the secondary chamber is closed and the red blood cells and residual hematocrit are dispelled out of the syringe. The threaded plunger with its secondary hollow chamber enables controlled capture of the plasma for forms a stable barrier between the plasma layers and the hematocrit components. The centrifuge and blood draw accessories are not included with the system and is not a part of the present submission. {1} # XI. Indications for Use The Adaptive Autologous Processing System™ (AAPS) is indicated to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of peripheral blood at the patient point-of-care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics. # XII. Summary of the Technological Characteristics The Adaptive Autologous Processing System is an improved syringe assembly, intended for the collection of whole blood and the separation of platelet rich plasma in a single device after they have been centrifuged. The Adaptive Autologous Processing System consists of a syringe with a hollow threaded plunger that provides a secondary chamber and locking collar that engages the thread plunger for the controlled collection of whole blood and the separation of platelet rich plasma The fundamental scientific technology, design, materials of construction, processing methods and mechanism of operation of the subject device are identical to the predicate device. All devices are provided as sterile concentrating systems, designed to concentrate and aid in separation of a starting source material (blood) by density using a centrifuge. All devices include a single-use, disposable receptacle (e.g. concentrating device, separator, centrifuge tube assembly, etc.) that is designed to accept a volume of blood, and then undergo centrifugal processing to obtain platelet rich plasma (PRP). The table below summarizes the comparison of characteristics between the subject and predicate device. | | Arthrex Double Syringe (ACP) (BK190406) | Adaptive Autologous Processing System (Subject Device) | | --- | --- | --- | | Indications for Use | The Arthrex Double Syringe (ACP) Kit is indicated for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of peripheral blood at the patient's point of care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics. | The Adaptive Autologous Processing System™ (AAPS) is indicated to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of peripheral blood at the patient point-of-care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics. | | Regulation | 21 CFR 864.9245 | Identical | | Device Class | II | Identical | | Device Code | ORG | Identical | | System Components | • Upper syringe • Lower syringe • Threaded cap | • Syringe assembly • Threaded cap | | Materials | Polypropylene, Thermoplastic elastomer, Silicone, ACD-A | Polycarbonate, Thermoplastic elastomer, silicone, Polyoxymethylene Copolymer | | Principle of Operation | Separation of blood based on density | Identical | | Energy source | Manual | Identical | | Method of Processing | Centrifugation | Identical | | Centrifuge Device | General purpose centrifuge | Identical | | Sterile | Yes | Yes | | Sizes | 15 mL | 25mL | {2} The Reference Device used for this submission, BK200449 Healeon Duet, has the identical design in every way. Only differences are labeling, by necessity to account for the difference in legal manufacturer and some subtle differences in the instructions for use: - include a second spin option, - change spin from 10 minutes @ 400RCF to 2 minutes @ 1500 RCF, and - add a dispelling of hematocrit step. # XIII. Discussion of the Non-Clinical Testing # Biocompatibility Testing Biocompatibility testing on the patient contacting materials of the device was conducted in accordance with ISO 10993-1 Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing within a Risk Management Process. Per ISO 10993-1, the Adaptive Autologous Processing System is categorized as an externally communicating device, with limited exposure (contact < 24 hours) with indirect blood contact. Testing included cytotoxicity (per ISO 10993-5), sensitization & intracutaneous reactivity (per ISO 10993-10), acute systemic toxicity (per ISO 10993-11), pyrogenicity per USP: 151 and USP 41-NF 36. # Sterilization Validation A sterilization dose qualification using the half-cycle method in compliance with ISO 11135:2014 was performed to validate an ethylene oxide sterilization process for Adaptive Autologous Processing System. Results demonstrated that the product is reliably sterilized to a 10⁻⁶ sterility assurance level (SAL) using these predetermined parameters. Genesis Biologics, Inc. intends to use this same procedure to increase sterilization efficiency, such as load capacity, configuration, or location post clearance. # Transport and Shelf-life A transportation validation per ASTM D4169 and a packaging shelf life validation per ISO 11607 was conducted using accelerated aging to demonstrate that the package is designed, manufactured, and packed in such a way that the characteristics and performances of the packaging during the intended use will not adversely be affected during the full life cycle of the device; that there is assurance that the device is sterile when placed in the market and will remain sterile, under the storage and transport conditions laid down, until the protective packaging is opened; and that the product will be kept without deterioration at the high level of cleanliness so as to minimize the risk of microbial contamination. # Usability / Human Factors A validation was conducted to demonstrate that for Adaptive Autologous Processing System user interface was designed and engineered to maximize the likelihood that this product will be safe and effective for the intended users, uses, and use environments. # Predicate Equivalency Evaluation A study was conducted to compare platelet concentrates produced by the for Adaptive Autologous Processing System and those produced by the predicate. Parameters included platelet yields, platelet recoveries, average PRP platelet concentration, pH, p-selectin expression on resting platelets, platelet response to ADP-stimulation, platelet function, platelet aggregation, hypotonic stress response, and Bone graft material retention. This evaluation demonstrated that the platelet concentrates obtained by the Adaptive Autologous Processing System is substantially equivalent to those of the predicate. {3} Additionally, the *Adaptive Autologous Processing System* and the predicate possess the same indications, device class, device code, principles of operation, methods of processing, sterility assurance level, and biocompatibility. The subject device uses components readily available to the user, and the size, where the larger size of the subject device provides increased usability. None of the differences negatively impact the device’s substantial equivalence when compared to the predicate. All validations, verifications, and qualifications passed the predetermined acceptance criteria. The *Adaptive Autologous Processing System* therefore has been shown to be substantially equivalent to the predicate. --- **Source:** [https://fda.innolitics.com/device/BK230807](https://fda.innolitics.com/device/BK230807) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com